AMLX Amylyx Pharmaceuticals, Inc. Insider Trading

CLO Gina Mazzariello sold 30,000 shares ($538.9K) via 10b5-1 plan; retains 179.1K shares post-sale

Gina Mazzariello, Chief Legal Officer at Amylyx Pharmaceuticals, executed 2 separate sales totaling 30,000 shares for $538,867.50 on 2026-07-09 and 2026-07-10 at blended average price of $17.96. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-04-09, meaning the sales were scheduled and not discretionary. The stock currently trades at $17.41, within the 52-week range of $6.56–$19.15, and is -9.1% from the 52-week high. The company reported zero revenue in its latest quarter and negative net income of $-41,284,000.00, with annual revenue growth of -100.0%. Given the scheduled nature of the 10b5-1 plan, this transaction reflects pre-established execution rather than a real-time discretionary response to current operational or market conditions. Investors should note that the CLO retained 179,090 shares post-transaction and that the company's fundamental performance shows significant challenges including no reported quarterly revenue and substantial operating losses.

Director Karen Firestone buys 3.8K shares of AMLX at $13.51; stock now down 30.0% from 52-week high, company unprofitable with $-41.3M net income

Karen Firestone purchased 3,800 shares at $13.51 on 2026-05-21, increasing her holdings by 6.0% to 66,900 shares total. The purchase occurs as AMLX trades at $13.01, down 30.0% from its 52-week high of $18.60 and down 11.7% over the past 30 days. Notably, Firestone's prior two purchases at AMLX (2025-12-23 and 2024-09-05) both showed positive 90-day returns of 30.4% and 146.7% respectively, establishing a pattern of well-timed entries at this ticker. However, the company's fundamentals present significant headwinds: latest quarterly revenue is $0.00, full-year net income was $-41.3M, and annual revenue growth declined 100.0% year-over-year, indicating an unprofitable business in significant financial distress.

Co-CEO Klee sells 138,188 shares in 2 transactions for $1.9M as AMLX stock surges 37.7% in 30 days

Klee Justin B., Co-Chief Executive Officer, executed 2 separate sales totaling 138,188 shares for $1,877,569.83 (blended average $13.59) on January 15-16, 2026. These sales represent a 3.9% reduction in his post-transaction holdings of 3,379,398 shares. The timing coincides with a sharp 37.7% rally over the preceding 30 days and placement near the 52-week high of $16.55, where the current price sits. The sales occurred while AMLX faces severe financial headwinds: the company reported zero revenue in the latest quarter, a negative net income of $-34,386,000, and annual revenue contraction of -77.1% year-over-year. A Co-CEO's substantial share disposition during a period of momentum, combined with the company's deteriorating operational metrics and cash burn, is material for investors evaluating management's commitment relative to public fundamentals.

AMLX Co-CEO Cohen sold 138,167 shares ($1.9M) at $13.59–$13.83; holds 3.38M shares post-sale as stock hits 52-week high of $16.55.

Co-Chief Executive Officer Joshua B Cohen executed 2 separate sales totaling 138,167 shares for $1,878,093.81 on January 15–16, 2026, at prices of $13.59 and $13.83. The current stock price of $16.55 is at the 52-week high, representing a +37.7% move over 30 days and +11.7% over 90 days. This sale reduces Cohen's holdings by 3.9% from 3,517,632 shares to 3,379,465 shares, but he retains substantial equity stake as Co-CEO. Notably, the company reported $0.00 revenue in its latest quarter and a net loss of $-34,386,000.00 for its most recent full fiscal year, with annual revenue declining -77.1%. The sale occurred as the stock neared or reached its 52-week peak, while the underlying business remains unprofitable with severely contracted revenues.

Director Karen Firestone bought 8,100 shares of AMLX at $12.45 on 2025-12-23, now valued 22% below 52-week high amid -77.1% revenue decline.

Karen Firestone, a Director at Amylyx Pharmaceuticals, purchased 8,100 shares at $12.45, adding to her position (now 63,100 shares post-transaction) during a period of significant stock weakness: the current price of $12.31 is -22.0% from the 52-week high and down 30-day change: -16.1%. The company faces severe operational headwinds—annual revenue growth has contracted by -77.1% year-over-year, net income was $-34,386,000.00 for the latest period, and quarterly revenue stands at $0.00, signaling a critical challenge in commercialization or market demand. Firestone's cross-ticker track record shows her prior open-market buys generated strong returns (avg 90d return +146.7%, 100.00% win rate), though her same-ticker history at AMLX includes only one measurable prior buy (2024-09-05, which returned +146.7% over 90 days); this current purchase occurs as the stock has declined materially from recent highs. The buy is discretionary and open-market, distinct from any scheduled trading plan, and occurs in the context of deteriorating fundamentals and ongoing stock weakness.

Director Zeiher buys 10,000 shares of AMLX at $3.70; stock down 46.2% from 52-week high amid -77.1% annual revenue decline and $-72.7M net loss.

Bernhardt G. Zeiher, as a director, initiated a 10,000-share position in Amylyx Pharmaceuticals at $3.70 on 2025-03-20, spending $37,005.00 in total value. This purchase occurs in a severely challenged operating environment: the company posted a net loss of $-72.7M in its most recent full fiscal year, latest quarterly revenue of only $416.0K, and an annual revenue decline of -77.1% year-over-year. The stock is currently trading at $3.78, still -46.2% from its 52-week high of $7.03, suggesting the market has already priced in substantial losses of confidence. The timing of this insider acquisition coincides with the stock trading near historically depressed levels within its 52-week range, though it has recovered +14.6% over the past 30 days. Without visibility into the director's broader portfolio strategy or prior transaction history at this ticker, the purchase represents a discrete open-market acquisition at a point when both the company's financial trajectory and the stock's valuation reflect severe operational distress.

CFO James M. Frates purchases 40,000 AMLX shares at $2.53, boosting stake 20.7%; part of cluster buy pattern with 2 other insiders in past 14 days

James M. Frates, CFO of Amylyx Pharmaceuticals, purchased 40,000 shares at $2.53 on 2024-09-12, increasing his holding by +20.7% to 233,464 shares total. The transaction occurs as the stock trades 87.2% below its 52-week high, and notably coincides with a cluster pattern in which 2 other insiders also purchased within the past 14 days. AMLX's fundamentals are severely distressed: the latest quarter showed $-1,023,000 revenue and $-72,700,000 net loss, though annual revenue growth is reported at +1612.9% (likely reflecting a recent pivot or acquisition-driven baseline expansion). Frates' prior open-market history shows a 100.00% well-timed rate on sells at the 90-day mark across his cross-ticker track record, signaling disciplined capital allocation decisions; however, his two prior sales at AMLX specifically (both on 2023-05-16) also demonstrated 90-day well-timing, with the stock declining -22.1% and -24.0% after those exits. This buy at a multi-year trough, paired with coordinated insider accumulation, contrasts with his recent history of tactical selling but warrants attention given the company's ongoing cash burn and depressed valuation context.

Director Karen Firestone buys 50,000 shares of AMLX at $2.13; stock down 88.1% from 52-week high.

Firestone purchased 50,000 shares at $2.13 on 2024-09-05, increasing her holdings to 55,000 shares from 5,000 shares. The stock now trades at $2.52, down 88.1% from the 52-week high of $21.19. Amylyx Pharmaceuticals is unprofitable with net income of $-72,700,000.00 in the latest quarter, though it reported annual revenue growth of +1612.9% year-over-year. Her prior open-market buy at this ticker showed a 90-day return of -78.8%, indicating a pattern of unfavorable timing outcomes. This buy occurred near a relative local bottom (stock has rebounded +44.8% over the past 90 days), but without scheduled trading plan disclosure, the context for this discretionary purchase—amid massive losses and a collapsed valuation—remains unclear.

Director Milne purchases 100,000 shares of AMLX at $2.20; stock down 89.9% from 52-week high of $21.82

Director George M Milne Jr purchased 100,000 shares at $2.20 on 2024-09-03, increasing his holdings by 13.2% to 858,571 shares. The purchase occurs at a severe discount: the stock is trading at -89.9% from its 52-week high of $21.82, though it has recovered 24.3% over the past 90 days and 11.7% over the past 30 days. The company is unprofitable with a net income of $-72,700,000.00 for the latest quarter and negative quarterly revenue of $-1,023,000.00, though annual revenue growth stands at 1612.9%. The combination of substantial insider accumulation at a deeply depressed valuation alongside extreme profitability losses presents a material disclosure event that warrants examination of whether this reflects conviction in a recovery thesis or other strategic considerations driving the transaction.